Mark Chin

Mark Chin is the current Director at Harpoon Therapeutics. Prior to this, they were a Principal at Longitude Capital from January 2012 to December 2016. Longitude Capital is a life sciences investment firm that focuses on venture growth investments in drug development and medical technology. Mark Chin was also a Consultant at The Boston Consulting Group (BCG) from January 2011 to December 2012 in their healthcare practice with an emphasis in early-stage biotechnology and pharmaceuticals.

From January 2010 to December 2010, Mark Chin was Corporate Development at Gilead Sciences where they worked on BioOncology Pipeline Market Planning for T-DM1. Mark also held the position of Market Planning at Genentech during the same time period.

Mark Chin has also been Investment Director at Arix Bioscience from January 2016 to December 2020 and Manager at Professional Service Solutions from January 2006 to December 2008. Mark started their career as Senior Business Analyst at Patpatia & Associates from January 2004 to December 2006 and then moved to JMI Equity as an Analyst from January 2004 to December 2004.

Mark Chin has a MBA from The Wharton School, a BS in Management Science and Computer Science from University of California San Diego, and an MSc in Biotechnology from University of Pennsylvania.